Edson-Heredia E - Search Results

1

Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.

Armstrong AW, Lynde CW, McBride SR, Ståhle M, Edson-Heredia E, Zhu B, Amato D, Nikaï E, Yang FE, Gordon KB. Armstrong AW, et al. JAMA Dermatol. 2016 Jun 1;152(6):661-9. doi: 10.1001/jamadermatol.2016.0269. JAMA Dermatol. 2016. PMID: 26953848

2

Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis.

Zhu B, Edson-Heredia E, Cameron GS, Shen W, Erickson J, Shrom D, Wang P, Banerjee S, Gordon KB. Zhu B, et al. Br J Dermatol. 2013 Dec;169(6):1337-41. doi: 10.1111/bjd.12610. Br J Dermatol. 2013. PMID: 24032554 Clinical Trial.

3

Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial.

Zhu B, Edson-Heredia E, Guo J, Maeda-Chubachi T, Shen W, Kimball AB. Zhu B, et al. Br J Dermatol. 2014 Nov;171(5):1215-9. doi: 10.1111/bjd.13065. Epub 2014 Oct 15. Br J Dermatol. 2014. PMID: 24749812 Clinical Trial.

4

A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab.

Edson-Heredia E, Banerjee S, Zhu B, Maeda-Chubachi T, Cameron GS, Shen W, Heffernan MP, Gordon KB, Leonardi CL. Edson-Heredia E, et al. J Eur Acad Dermatol Venereol. 2016 May;30(5):864-5. doi: 10.1111/jdv.13032. Epub 2015 Mar 13. J Eur Acad Dermatol Venereol. 2016. PMID: 25773781 Clinical Trial. No abstract available.

5

Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis.

Kimball AB, Naegeli AN, Edson-Heredia E, Lin CY, Gaich C, Nikaï E, Wyrwich K, Yosipovitch G. Kimball AB, et al. Br J Dermatol. 2016 Jul;175(1):157-62. doi: 10.1111/bjd.14464. Epub 2016 May 8. Br J Dermatol. 2016. PMID: 26852717 Clinical Trial.

6

Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.

Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Nikaï E, Zhu B, Edson-Heredia E, Carlier H, Lin CY, Goldblum O, Yosipovitch G. Kimball AB, et al. J Am Acad Dermatol. 2016 Dec;75(6):1156-1161. doi: 10.1016/j.jaad.2016.07.034. Epub 2016 Sep 27. J Am Acad Dermatol. 2016. PMID: 27692498 Clinical Trial.

7

Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.

Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin M. Langley RGB, et al. Qual Life Res. 2020 Feb;29(2):369-380. doi: 10.1007/s11136-019-02296-5. Epub 2019 Oct 26. Qual Life Res. 2020. PMID: 31655974 Clinical Trial.

8

Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations.

Blauvelt A, Griffiths CEM, Lebwohl M, Mrowietz U, Puig L, Ball S, Zhang L, Edson-Heredia E, Warner M, Zhu B, Lin CY, Nikaï E, Dey D, Mallbris L, Reich K. Blauvelt A, et al. Br J Dermatol. 2017 Aug;177(2):587-590. doi: 10.1111/bjd.15463. Epub 2017 Jul 3. Br J Dermatol. 2017. PMID: 28301048 Clinical Trial. No abstract available.

9

Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey.

Armstrong A, Edson-Heredia E, Zhu B, Burge R, Bell S, Crowley JJ, Smith S. Armstrong A, et al. Among authors: edson heredia e. Adv Ther. 2022 Jun;39(6):2657-2667. doi: 10.1007/s12325-022-02124-2. Epub 2022 Apr 11. Adv Ther. 2022. PMID: 35399114 Free PMC article.

10

Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses.

Armstrong AW, Edson-Heredia E, Naegeli AN, Burge R, Poon JL, Anatchkova M, Sun L, Zhu B, Wyrwich KW. Armstrong AW, et al. J Dermatolog Treat. 2020 Aug;31(5):452-459. doi: 10.1080/09546634.2019.1623370. Epub 2019 Jul 15. J Dermatolog Treat. 2020. PMID: 31157576

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37 results

Search Page